Abstract
The pressure for health care systems to provide more resource-intensive health care and newer, more costly therapies is significant, despite limited health care budgets. It is not surprising, then, that demonstration that a new therapy is effective is no longer sufficient to ensure that it can be used in practice within publicly funded health care systems. The impact of the therapy on health care costs is also important and considered by decision makers, who must decide whether scarce resources should be invested in providing a new therapy. The impact of a therapy on both clinical benefits and costs can be estimated simultaneously using economic evaluation, the strengths and limitations of which are discussed. When planning a clinical trial, important economic outcomes can often be collected alongside the clinical outcome data, enabling consideration of the impact of the therapy on overall resource use, thus enabling performance of an economic evaluation, if appropriate.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Reference
1. Manns, B., Taub, K., Donaldson, C. (2000) Economic evaluation and end-stage renal disease: From basics to bedside. Am J Kidney Dis 36, 12–28.
Hirth, R. A. (2007) The organization and financing of kidney dialysis and transplant care in the United States of America. Int J Health Care Finance Econ 7 (in press).
3. Lee, H., Manns, B., Taub, K., Ghali, W. A., Dean, S., Johnson, D., Donaldson, C. (2002) Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. Am J Kidney Dis 40, 611–622.
4. Tomson, C. R. (2000) Recent advances: Nephrology. BMJ320, 98–101.
Manns, B., Mendelssohn, D., Taub, K. (2007)The economics of end-stage renal disease care in Canada: Incentives and impact on delivery of care. Int J Health Care Finance Econ 7 (in press).
6. Donaldson, C., Shackley, P., Detels, R., Holland, W. W., McEwan, J., Omenn, G. S. (1997) Economic evaluation, in Oxford Textbook of Public Health, 3rd ed. Oxford University Press, Oxford, pp. 849–870.
7. Manns, B., Doig, C. J., Lee, H., Dean, S., Tonelli, M., Johnson, D., Donaldson, C. (2003) Cost of acute renal failure requiring dialysis in the intensive care unit: Clinical and resource implications of renal recovery. Crit Care Med 31, 449–455.
8. Tonelli, M., Klaarenbach, S., Jindal, K., Manns, B. (2006) Economic implications of screening strategies in arteriovenous fistulae. Kidney Int 69, 2219–2226.
9. Fenton, S. S., Schaubel, D. E., Desmeules, M., Morrison, H. I., Mao, Y., Copleston, P., Jeffery, J. R., Kjellstrand, C. M. (1997) Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates. Am J Kidney Dis 30, 334–342.
10. Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., O'Dea, R., Murray, D. C., Barre, P. E. (1998) Mode of dialysis therapy and mortality in end-stage renal disease. J Am Soc Nephrol 9, 267–276.
11. Bloembergen, W. E., Port, F. K., Mauger, E. A., Wolfe, R. A. (1995) A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 6, 177–183.
12. Collins, A. J., Hao, W., Xia, H., Ebben, J. P., Everson, S. E., Constantini, E. G., Ma, J. Z. (1999) Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 34, 1065–1174.
13. Gerard, K., Mooney, G. (1993) QALY league tables: Handle with care. Health Econ 2, 59–64.
14. Mauskopf, J., Rutten, F., Schonfeld, W. (2003) Cost-effectiveness league tables: Valuable guidance for decision makers? Pharmacoeconomics 21, 991–1000.
15. Drummond, M., O'Brien, B., Stoddart, G., Torrance, G. (1997) Methods for the Economic Evaluation of Health Care Programmes, 2nd ed. Oxford University Press, Oxford.
16. Manns, B., Tonelli, M., Shrive, F., Wiebe, N., Klarenbach, S., Lee, H., Culleton, B. (2006) Sevelamer in Patients with End-Stage Renal Disease: A systematic Review and Economic Evaluation. Technology report no. 71. Canadian Agency for Drugs and Technologies in Health, Ottawa.
Canadian Coordinating Office for Health Technology Assessment. (2006) Guidelines for Economic Evaluation of Pharmaceuticals. Canadian Coordinating Office for Health Technology Assessment, Ottawa.
18. Drummond, M. F., Jefferson, T. O., BMJ Economic Evaluation Working Party. (1996) Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 313, 275–283.
19. Gold, R., Siegel, J., Russell, L., Weinstein, M. (1996) Cost-Effectiveness in Health and Medicine. Oxford University Press, New York.
20. Donaldson, C., Currie, G., Mitton, C. (2002) Cost effectiveness analysis in health care contraindications. BMJ 325, 891–894.
21. Laupacis, A., Feeny, D., Detsky, A. S., Tugwell, P. X. (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146, 473–481.
22. Schwappach, D. L. (2003) Does it matter who you are or what you gain? An experimental study of preferences for resource allocation. Health Econ 12, 255–267.
23. Shrive, F. M., Ghali, W. A., Lewis, S., Donaldson, C., Knudtson, M. L., Manns, B. J. (2005) Moving beyond the cost per quality-adjusted life year: Modelling the budgetary impact and clinical outcomes associated with the use of sirolimus-eluting stents. Can J Cardiol 21, 783–787.
24. Miners, A. H., Garau, M., Fidan, D., Fischer, A. J. (2005) Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: Retrospective study. BMJ 330, 65.
25. Huybrechts, K. F., Caro, J. J., Wilson, D. A., O'Brien, J. A. (2005) Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 8, 549–561.
26. Chertow, G. M., Burke, S. K., Raggi, P., Treat-to-Goal Working Group. (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62, 245–252.
27. Huybrechts, K. F., Caro, J. J., London, G. M. (2005) Modeling the implications of changes in vascular calcification in patients on hemodialysis. Kidney Int 67, 1532–1538.
28. Suki, W., Zabaneh, R., Cangiano, J., Reed, J., Fischer, D., Swan, S., Block, G., Dillon, M., Blair, A., Burke, S. (2005) The DCOR Trial: A Prospective, Randomized Trial Assessing the Impact on Outcomes of Sevelamer in Dialysis Patients. American Society of Nephrology, Philadelphia.
29. O'Brien, B. (1996) Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? Med Care 34, DS99–108.
30. Ramsey, S. D., Berry, K., Etzioni, R., Kaplan, R. M., Sullivan, S. D., Wood, D. E. (2003) Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med 348, 2092–2102.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Manns, B.J. (2008). The Role of Health Economics within Clinical Research. In: Barrett, B., Parfrey, P. (eds) Clinical Epidemiology. Methods in Molecular Biology™, vol 473. Humana Press. https://doi.org/10.1007/978-1-59745-385-1_14
Download citation
DOI: https://doi.org/10.1007/978-1-59745-385-1_14
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-58829-964-2
Online ISBN: 978-1-59745-385-1
eBook Packages: Springer Protocols